Ori Biotech and Charles River Laboratories Collaborate to Accelerate Life-Saving Cell and Gene Therapy Development and Manufacturing
Mizuho Securities Maintains Charles River(CRL.US) With Hold Rating, Announces Target Price $210
Mizuho Securities analyst Ann Hynes maintains $Charles River(CRL.US)$ with a hold rating, and sets the target price at $210.According to TipRanks data, the analyst has a success rate of 63.3% and a
Charles River Comparative Study Reveals That Kytopen's Flowfect Tx Platform Outperforms Conventional Electroporation Platforms
Charles River Laboratories, CEBINA Partner to Accelerate Neurodegenerative Drug Development
Unusual Options Activity: WBD, CRL and Others Attract Market Bets, WBD V/OI Ratio Reaches 73.9
EST Sep 16th Morning Delivery - In the last two hours of trading, 7 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.
Shareholders in Charles River Laboratories International (NYSE:CRL) Are in the Red If They Invested Three Years Ago